|Bid||0.2450 x 0|
|Ask||0.2500 x 0|
|Day's Range||0.2450 - 0.2600|
|52 Week Range||0.1200 - 0.3200|
|Beta (5Y Monthly)||1.92|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr. 27, 2021 - May 03, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Has executed a Collaborative Research Agreement with the National Microbiology Laboratory, Public Health ...
TORONTO, ON / ACCESSWIRE / April 9, 2021 / Theralase® Technologies Inc.Under the terms of the agreement, Theralase® and PHAC are collaborating on the development and optimization of a COVID-19 vaccine by treating the SARS-CoV-2 virus grown on cell lines with Theralase®'s patented PDC and then light activating it with Theralase®'s proprietary TLC-3000A light technology to inactivate the virus and create the fundamental building blocks of a COVID-19 vaccine.
TORONTO, ON / ACCESSWIRE / March 29, 2021 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds ("PDC") and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today the launch of the Theralase® Anti-Cancer Therapy ("ACT") research centre located within the Li Ka Shing Knowledge Institute of St.